Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

NextEdge Admin

15 Nov 2024

2 min 13 sec

German biotech giant BioNTech has acquired Chinese oncology startup Biotheus in a deal worth $950 million, expanding its oncology treatment portfolio and presence in China. Biotheus specializes in developing antibodies for oncological and inflammatory diseases, including BNT327/PM8002, a late-stage trial antibody product.

BioNTech plans to advance BNT327/PM8002, which has shown promising results in treating various tumor types. The antibody has demonstrated a positive safety profile and notable antitumor activity, particularly in non-small cell lung cancer and triple-negative breast cancer when combined with chemotherapy. Future trials will explore integrating the antibody with BioNTech’s proprietary antibody-drug conjugates.

Ugur Sahin, BioNTech’s CEO, highlighted the therapy’s potential to exceed traditional checkpoint inhibitors in multiple oncology indications. “We aim to combine this with our mRNA vaccines and targeted therapies to enhance outcomes for patients with solid tumors,” Sahin said.

The acquisition grants BioNTech access to Biotheus’ biologics manufacturing facility and a 300-strong R&D team, boosting its innovation capacity. Biotheus CEO Xiaolin Liu emphasized the potential of their discovery platform and pipeline of investigational assets.

The move aligns with BioNTech’s strategic expansion in the fast-growing Chinese biotech sector, joining global players like Pfizer, GSK, and Sanofi. BioNTech’s $25 million investment in MediLink’s solid tumor-focused ADC further underlines its regional commitment. This acquisition positions BioNTech to strengthen its oncology research and clinical capabilities, leveraging Biotheus’ innovative approaches to antibody development.